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remains the largest cause of mortality worldwide. Much has been made of the role of endothelial dysfunction
in CAD, but tools to measure and augment its progression are lacking. Recent cellular biomarkers have been
found to be involved in endothelial dysfunction and the presence of CAD. As the role of these biomarkers
becomes more defined, can the measurement of endothelial progenitor cells now predict the risk of
experiencing future cardiovascular events?
Methods: Exhaustive search of available medical literature was performed on the databases CINAHL, Web of
Science, and Medline-OVID. These were searched using the keywords “cardiovascular events,” “endothelial
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Results: Three observational trials met inclusion requirements. One of these studies evaluated the correlation
between endothelial progenitor cells (EPCs) and cardiovascular (CV) risk along with endothelial function
This study was able to establish a significant correlation between the number of EPCs and their functional
ability and endothelial dysfunction in patients with cardiovascular disease. The other two studies utilized a
prospective approach and measured EPC numbers at baseline and then followed the sample to record the
number of CV events. The first of these two studies was able to demonstrate that reduced numbers of EPC
independently predicts atherosclerotic disease progression, while the second showed that EPC levels can
predict the occurrence of CV events and aide in risk stratification of people with increased CV risk.
Conclusion: Endothelial progenitor cells have been proven to have a role in endothelial dysfunction,
cardiovascular disease progression, and now risk assessment. While many factors play into the overall
mechanism in which EPC levels affect cardiovascular risk and endothelial repair, monitoring blood levels of
EPCs has become a feasible biomarker that can be added to further stratify ones CV risk profile.
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Abstract 
 
Background: Despite advances in treatment and risk factor management, coronary artery 
disease (CAD) remains the largest cause of mortality worldwide. Much has been made of 
the role of endothelial dysfunction in CAD, but tools to measure and augment its 
progression are lacking. Recent cellular biomarkers have been found to be involved in 
endothelial dysfunction and the presence of CAD. As the role of these biomarkers 
becomes more defined, can the measurement of endothelial progenitor cells now predict 
the risk of experiencing future cardiovascular events? 
 
Methods:  Exhaustive search of available medical literature was performed on the 
databases CINAHL, Web of Science, and Medline-OVID. These were searched using the 
keywords “cardiovascular events,” “endothelial cells,” and “risk assessment”. All 
included studies were assessed for quality using the GRADE scale. 
 
Results:  Three observational trials met inclusion requirements. One of these studies 
evaluated the correlation between endothelial progenitor cells (EPCs) and cardiovascular 
(CV) risk along with endothelial function This study was able to establish a significant 
correlation between the number of EPCs and their functional ability and endothelial 
dysfunction in patients with cardiovascular disease. The other two studies utilized a 
prospective approach and measured EPC numbers at baseline and then followed the 
sample to record the number of CV events. The first of these two studies was able to 
demonstrate that reduced numbers of EPC independently predicts atherosclerotic disease 
progression, while the second showed that EPC levels can predict the occurrence of CV 
events and aide in risk stratification of people with increased CV risk. 
 
Conclusion:  Endothelial progenitor cells have been proven to have a role in endothelial 
dysfunction, cardiovascular disease progression, and now risk assessment. While many 
factors play into the overall mechanism in which EPC levels affect cardiovascular risk 
and endothelial repair, monitoring blood levels of EPCs has become a feasible biomarker 
that can be added to further stratify ones CV risk profile. 
 
Keywords:  Endothelial progenitor cells, cardiovascular events, risk assessment, 
prognosis 
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BACKGROUND 
 Cardiovascular disease (CVD) is the number one killer of people in the United 
States and worldwide. Every minute, an American dies from coronary artery disease 
(CAD) and 37% of people who suffer from an acute cardiovascular event will die within 
the year. The treatment and recognition of CAD has been improving and a dramatic 
decline has been experienced in death rates over the last 35 years. This is in part from 
new targeted treatments of CAD and management of cardiovascular risk factors. Despite 
this improvement, CAD still affects about 16 million adults in the US and is still 
responsible for approximately one in five deaths in the US. This accounts for around 600 
000 deaths per year in the United States.1 Coronary artery disease alone is responsible for 
$108.9 billion cost to the United States including health care costs, medication, and lost 
productivity.2 Since the incidence of CAD increases with increasing age, the US 
population will observe an increase in the burden of CAD on our medical system.1 
 It is well known that presence of traditional cardiovascular risk factors: age, 
family history of premature  heart disease, diabetes, male gender, smoking, hypertension, 
hyperlipidemia, obesity, and physical inactivity put one at a higher risk of developing 
CAD and contribute to endothelial dysfunction3; less understood is how these factors 
interplay with the pathogenesis of CAD. CAD has now has been established as an 
endovascular inflammatory process that triggers a cascade of destructive events, but what 
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causes this process to start? More importantly, how can clinicians measure this 
dysfunction and attempt to predict its course?  
  Endothelial dysfunction is a term that describes the shift from healthy 
endothelium to a damaged, pro-inflammatory, pro-coagulative, pro-vasoconstrictive 
endothelium which lends itself to cardiovascular complications.4 The recognition of this 
process as a key part of the pathogenesis of CAD has led to the investigation of several 
biomarkers that play roles in this dysfunction: circulating endothelial cells (CECs), 
endothelial microparticles (EMPs), and endothelial progenitor cells (EPCs). Current 
consensus is that CECs are mature endothelial cells that shed from the vascular lining in 
response to injury. EMPs are similar in the fact that their presence is often attributed with 
injury to the endothelial lining. EPCs are immature endothelial cells that originate from 
bone marrow; these cells are currently associated with vascular regeneration and 
endothelial repair.5 While lower levels of this cell type would indicate inability to repair, 
there also has been an association of increased number of EPCs and acute ischemic 
events.6,7 It has also been shown that differentiation of these cells has led to the new 
growth of vascular structures.5 This has led to investigating these cells as different 
therapeutic options where new vessel growth is indicated.8 
 Recording endothelial dysfunction in subjects is not a simple variable to measure. 
Most often this is done non-invasively through flow mediated dilation of the brachial 
artery which takes advantage of the fact that shear stress applied to a vessel will cause 
nitric oxide release and subsequent vasodilation.3,9 Other methods include invasively 
measuring vascular response to acetylcholine infusion.3,10 Measuring the levels of these 
cellular biomarkers is best accomplished through flow cytometry.11 This process involves 
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blood being drawn from a subject and then staining of cells to allow detection of specific 
receptors that are associated with each type of cell. EPCs are mainly categorized into 
those which express CD34+/KDR+ receptors or CD133+ receptors,5,12 KDR is another 
name for vascular endothelial growth factor (VEGF) receptor. Occasionally, these 
CD133+ cells are referred to as “immature” EPCs while CD34+ are thought to be 
“mature” EPCs, but more commonly these cells are referred to in terms of “early-growth” 
and “late-growth” EPCs which refers to length of time to grow on a cultured medium and 
the expression of other hematopoietic markers that tell their lineage from either 
hematopoietic stem cells or vascular stem cells.8 Both lines are thought to have roles in 
endothelial modification. 
 Other measurable characteristics of these cells are the colony-forming and 
migratory ability; these are measured on cultured growth assays.5 After a period of 
growth, the amounts of colony forming units (CFU-ECs) are counted and migration 
measured using fluoroscopy. These characteristics are thought to be tied to these cells 
functional capabilities.8 Speculation also lies in the process in which these cells are called 
to the area of injury as an area where disruption can occur. It has been theorized that 
many inflammatory cytokines and communication through the Akt-nitric oxide synthase 
pathway control the mobilization of these cells to areas of injury.13  
It has been seen that different disease processes as well as possessing certain 
cardiovascular risk factors can affect endothelial progenitor cells. Number of cells, 
mobilization to injury, and colony forming ability are all shown to be affected.14 With the 
observation that these factors have been associated with decreases in EPCs and EPC 
functionality, and that low numbers of EPCs are associated with endothelial dysfunction, 
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the question becomes what role do EPCs play in cardiovascular disease. Much has been 
done in determining the function and purpose of these cells. What if they can help with 
predicting future cardiovascular events and stratifying risk in an already diseased 
population? 
METHODS 
 A comprehensive search of the medical literature was done by searching the 
databases CINAHL, WEB OF SCIENCE, and MEDLINE-OVID using the keywords 
“cardiovascular events,” “endothelial cells,” and “risk assessment.” The returned search 
results were then screened for relevance by including only English articles and study that 
utilized human subjects. Further exclusion criteria were applied that include: studies 
where epithelial progenitor cells (EPC) were not a primary area of focus, studies that 
focused on EPC’s as a therapeutic option, those not related to cardiovascular risk 
assessment, and those that looked at EPC’s in acute events. The bibliographies of 
relevant studies were then searched for further relevant studies. All included studies were 
then assessed for quality using the Grading of Recommendations, Assessment, 
Development and Evaluation (GRADE) scale15; however, no exclusions were made 
based on these results. 
RESULTS 
 An initial search yielded 126 results. These were screened and narrowed to two 
relevant articles10,13 after application of inclusion criteria, all being observational trials. A 
search of the bibliographies yielded one additional relevant study16 that met inclusion 
criteria, which is also observational in design. See Table 1. 
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WERNER (2005) ET AL 
 This prospective observational trial16 looked to answer the question if the number 
of circulating endothelial progenitor cells would correlate with cardiovascular outcomes. 
In order to answer this question the authors assessed the number of endothelial progenitor 
cells in 587 patients who underwent coronary angiography between March 2003 and 
January 2004. They then followed these patients for a follow-up period of 12 months to 
record the amount of cardiovascular outcomes or events that occurred. Cardiovascular 
events were defined as death from cardiovascular cause or occurrence of first 
cardiovascular event, which included acute myocardial infarction, hospitalization from 
cardiovascular event, need for revascularization, and death from CV cause. Death from 
all causes was also monitored.16 
 Subjects who underwent angiography were scored for disease presence by two 
independent interventional cardiologists. Of the original 587 patients evaluated 49 
patients without evidence of CAD on angiography and 19 patients with malignant or 
inflammatory disease or severe acute ischemia were excluded. Informed consent was 
obtained on all patients and the study protocol was approved by the ethics committee of 
the University of Saarland. The 12 patients who did not complete the follow-up were also 
excluded from the final results leaving a total of 507 subjects.16 
 Subjects were assessed for previous cardiovascular events and follow-up data 
based on previous medical records and personal interviews. Individual risk factors for 
CVD and current treatment regimens were taken into account for risk stratification and 
included in statistical analysis. Causes of death were determined by examination of 
hospital records, autopsy reports, and medical files of the subject’s general practitioners. 
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Flow cytometry was done on arterial blood samples and samples were stained looking for 
CD34+ cells, KDR+ cells, and CD133+ cells. Samples were also assessed for colony 
forming ability.16 
 To better perform statistical analysis on results, values of EPCs were analyzed as 
categorical variables after log transformation to normalize distribution. Specific 
thresholds were then determined to categorize subjects into cohorts based on their EPC 
levels at the time of enrollment, levels being either “low,” “medium,” or “high.” 
Continuous variables were assessed for normal distribution using the Kolmogorov-
Smirnov test and one-way analysis-of-variance test was used for comparisons of 
categorical variables. Multivariate proportional-hazards regression analysis was 
performed to determine the association between EPC counts and each outcome measured. 
Analyses were adjusted for age, sex, smoking status, hypertension, diabetes, 
hyperlipidemia, left ventricular ejection fraction, percutaneous coronary intervention, 
diagnosis of ACS at time of enrollment, severity of CAD, and treatment with ACE-I, 
beta-blockers, statins, or platelet inhibitors. Survival was determined with the Kaplan-
Meier method and Cox regression analysis, and statistical significance was found with a 
p-value < 0.05. All data analyses and event classifications were performed by 
investigators blinded to EPC status of patients.16 
 Investigators found that cumulative event-free survival increased in a step-wise 
fashion across increasing levels of baseline endothelial progenitor cells in regards to 
deaths from cardiovascular causes (p = 0.01)  and occurrence of one’s first cardiovascular 
event (p < 0.001). Hospitalization and revascularization were also found to be more 
frequent occurrences in the subgroup with lower EPC counts. It was found that increasing 
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numbers of CD34+/KDR+ endothelial cells were associated with a decreased risk of 
death from cardiovascular causes. The risk of death from CV causes was found to be 
increased by greater than 3 times  when comparing subjects in the low EPC group to 
those in the highest EPC group, and resulting in a hazard ratio of 0.31 (95% CI 0.16 to 
0.63). After adjustment for variable listed above, the association between increasing 
levels of EPCs and decreased risk of CV death remained significant (p = 0.001).16 
It was also shown that decreasing levels of endothelial progenitor cells were 
associated with the development of a first major cardiovascular event. After multivariate 
analysis for covariates it was confirmed that there was statistically significant association 
between CD34+/KDR+ EPCs and the occurrence of one’s first major CV event with a 
hazard ratio of 0.74 (95% CI 0.62 to 0.89, p = 0.002). The results followed a similar trend 
for CD133+ endothelial progenitor cells. The cumulative event-free survival also 
increased in a step-wise fashion with increasing baseline levels for colony forming units 
of endothelial cells. This was shown to maintain significance after analysis for a person’s 
first major cardiovascular event (p = 0.03), revascularization (p = 0.01), and 
hospitalization (p = 0.01). A multivariate analysis confirmed these associations and also 
showed a hazard ratio of 0.68 (995% CI 0.49 to 0.96, p = 0.03) for one suffering their 
first major CV event.16 
Through this data the authors were able to illustrate that a single measurement of 
CD34+/KDR+ endothelial progenitor cells can be a useful tool in predicting CV 
outcomes in patients with known CAD.16 The associations of these cells and the 
outcomes measured were found to be independent of disease severity, diagnosis of acute 
coronary syndrome, cardiovascular risk factors, or current drug therapy. The authors infer 
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that these finding suggest that EPCs contribute to the restoration of the endothelial 
monolayer. They admit that through their findings they were not able to establish a 
significant connection between EPC levels and death of all causes or acute myocardial 
infarction. They put forth that an excess of deaths from non-cardiovascular cause could 
have led to this finding. They also suggest that it is possible that there is an up regulation 
of EPCs during acute ischemic events. They call for more research to help understand the 
complex interplay between EPCs and acute myocardial infarctions. They also call for 
more research to further enlighten the connection between congestive heart failure and 
EPC dysfunction, as this can contribute to the dysfunction in patients with AMI. 
Regardless, they state that this biomarker has a place in the stratification of patients with 
CAD and a future lies in therapeutic targeting of these cells and vascular healing.16 
SCHMIDT-LUCKE ET AL 
In this prospective observational trial,13 the authors looked to determine whether 
circulating EPC levels correlated with atherosclerotic disease progression. In order to test 
this question, the authors recruited 120 subjects from a single center between the months 
of October 2000 and June 2004.  These 120 subjects were stratified into three groups; 
those with stable CAD, those with unstable CAD which was termed the acute coronary 
syndrome (ACS) group and a control group. The stable CAD group (n=44) was defined 
as having angiographically documented CAD in the absence of ACS in the previous 3 
months before blood samples were drawn. People with unstable CAD (n=33) were 
defined as having de novo angina or angina at rest. They were also stratified as for 
troponin positivity to account for myocardial necrosis on EPC levels. Moreover, extent of 
 - 15 - Revised 04Mar2014 
CAD to number of coronary arteries affected was measured. Healthy subjects (n=43) 
were defined as having no CAD by history and physical exam.13 
Further inclusion and exclusion criteria were applied to the groups. Inclusion 
criteria was defined as persons aged 18 to 85 years, with signed informed consent, 
documented CAD for subjects with stable CAD or ACS or acute myocardial infarction 
(AMI). Exclusion criteria was defined as persons with clinical or biochemical evidence 
for the presence of concomitant inflammatory disease, chronic renal insufficiency 
(creatinine > 1.4 mmol/L), impaired left ventricular ejection fraction (EF < 45%), 
autoimmune or malignant disease, thrombocytopenia (platelets <100 000/L), anemia 
(hemoglobin < 8.5 g/dL), inability to understand the consent form, participation in or 
consent to participate in another study, previous coronary artery bypass grafting (CABG), 
severe peripheral artery disease, or atrial fibrillation.13   
 Levels of EPC were measured using flow cytometry. Clinical long-term follow-up 
of the subjects was performed using a questionnaire that was sent to the subjects and 
telephone contact. Through this form all information regarding potential CV events was 
validated by source data, including coronary angiogram analysis, discharge letters, or 
hospital charts. CV death was defined as death from myocardial infarction, or 
documented sudden death. Further events were recorded including unstable angina 
events, AMI, and progression of CVD by need of new revascularization either by 
percutaneous coronary intervention (PCI) or CABG due to documented ischemia.13 
 Statistical analysis of results was applied toward all results. Continuous variables 
were tested for normal distribution with the Kolmogorov-Smirnov test and non-normally 
distributed variables (age, CV risk factors, EPC numbers, extent of disease, high-
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sensitivity C-reactive protein score) were compared by the Mann-Whitney U test. 
Comparisons between groups were done by the t test or ANOVA for normally distributed 
variables with > 2 subgroups and by the Kruskal-Wallis test for non-normally distributed 
variables. Comparison of categorical variable was done using the Pearson x2 test. 
Multivariate linear regression analysis and nonparametric bivariate correlation were used 
to correlate circulating EPC levels with CV risk factors, and regression analysis was 
performed against risk factors to determine independent determinants of EPC counts. 
Cumulative event-free survival was univariately evaluated by Kaplan-Meier analysis, and 
Cox proportional-hazard ratio was used to estimate relative risk for major adverse cardiac 
events (MACE) association with identified variables. Statistical significance was 
assumed if the null hypothesis could be rejected at a p <= 0.05.13 
 Through this analysis the authors were able to show that the control group had 
significantly higher levels of EPCs when compared to subjects with documented CAD. 
By univariate analysis of  the entire cohort, the classic risk factors of CAD: age, 
hypertension, smoking, family history, as well as disease progression, and atherosclerotic 
extent, were all found to be inversely related to the number of circulating endothelial 
progenitor cells. Multivariate analysis showed that age and positive family history of 
CAD remained as the only independent predictors of EPC levels.13  
During the follow-up period for this study13 it was found that 11 subjects suffered 
from a cardiovascular event. Subjects that suffered an event were found to have 
significantly lower EPC levels when drawn at the beginning of the study at 0.0067 +/- 
0.0097 vs. 0.02 +/- 0.02 in patients without a CV event. Subjects were also arranged into 
quintiles according to EPC levels and those subjects in the lowest quintile were found to 
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have significantly (p < 0.05) more cardiovascular events. Kaplan-Meier analysis found 
that across subjects, those that had EPC levels below the threshold of a CD34+/KDR+ 
count of 0.0038 had a significantly higher incidence of CV events. It was found, that the 
crude hazard ratio (HR) for suffering from CV event during follow-up with an EPC count 
below this threshold was 6.3, p = 0.003.  When this number was adjusted for disease 
activity and risk factors of CVD, being below this threshold for EPCs was still associated 
with a significant, nearly 4-fold increased risk of suffering from a CV event (HR 3.9, p = 
0.036).13 
The authors were able to conclude through this study13 that reduced EPC levels 
independently predict atherosclerotic disease progression and future cardiovascular 
events. This supports that endogenous repair of vasculature has an important role in 
modulating the clinical course of CAD. They recognize that by measuring only 
CD34+/KDR+ EPC and leaving out immature CD133+ cells, they are possibly missing 
mechanistic insights to colony forming capacity and migratory capacity of EPCs. While 
they declare that a link between CV risk factor presence and reduced numbers of EPC 
exists, they call for further research that identifies more clear correlations between EPC 
functional capacity and endogenous vascular repair.13 
WERNER (2007) ET AL 
 This particular study10 was designed by the authors to correlate endothelial 
function with endothelial progenitor cells in patients with coronary artery disease (CAD). 
Observational in design, the authors examined EPC levels and functional ability as well 
as endothelial function in patients with known CAD. Subjects were enrolled in the study 
and all received a coronary angiogram due to suspected myocardial ischemia. Only 
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subjects with <= 50% luminal reduction and no flow limiting stenosis in at least one 
coronary artery were included. Subjects were excluded if there was a malignant process 
or if there was inflammatory disease present. Also if there was evidence of acute 
myocardial ischemia subjects were excluded. All patients were fasting for 12 prior to 
cathertization, and all blood samples were drawn prior to catheterization.  Ninety subjects 
were eligible and one was excluded based on difficulty of their coronary anatomy. 
Medical histories including CV risk factors, previous and present CV events, current 
medication regiment, and vital signs were obtained from medical files and personal 
interview for stratification and statistical analysis of subjects.10 
 During catheterization, acetylcholine was infused into one coronary artery in an 
attempt to induce vasospasm, and angiography was performed to record luminal diameter 
and differences were recorded in comparison to angiography without infusion of any 
drug. Flow cytometry was also done in attempt to measure each individual’s amount of 
endothelial progenitor cells. After samples were drawn, an attempt to culture these cells 
was made to determine the amount of colony forming units and ascertain functional 
ability. All data of EPC and colony forming unit endothelial cell (CFU-EC) levels were 
converted using natural-log methods to express this data as continuous variables. 
Univariate and non-parametric bivariate correlations were performed using the Pearson 
correlation coefficient when data was normally distributed. Stepwise linear regression 
analysis was done where indicated to determine independent variables that could 
influence the prediction of EPC and CFU-EC changes in peripheral blood and statistical 
significance was assumed with a p-value < 0.05.10 
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 Of the eighty-nine patients remaining, it was shown that endothelial function  
significantly correlated with the number of either CD133+  or CD34+/KDR+ EPC’s with 
a regression value of r = 0.239, p = 0.024 and r = 0.427, p < 0.001 respectively. This 
showed that subjects that had lower total number of EPCs suffered from severe 
endothelial dysfunction. Stepwise linear regression analysis demonstrated that this was 
finding was independent of age, gender, diabetes, hypertension, hyperlipidemia, family 
history of premature CAD, smoking, and statin treatment (p < 0.001 for CD34+/KDR+ 
and p = 0.017 for CD133+). Function of EPC was quantified by the ability of isolated 
cells to form colony forming units. Initial analysis showed that EPC function correlated 
with endothelial function (r = 0.271, p = 0.038), thus showing that poor EPC function 
would associate with greater endothelial dysfunction. However, after linear regression 
analysis, accounting for the same variables, this was no longer found to be significant.10 
 These results show that the number of circulating endothelial progenitor cells 
closely correlate with endothelial function, independent of other risk factors associated 
with cardiovascular disease. By this, the authors infer that the integrative regenerative 
capacity of EPCs may be relevant toward the state of vascular dysfunction. They also 
conclude that these cells are involved in the pathogenesis of not only endothelial 
dysfunction, but also atherosclerosis and CAD. The precise factors that regulate these 
cells are not as well understood. The authors speculate that it is possible that certain 
cytokines take on this responsibility. They call for more research into the factors that 
regulate these cells numbers in the human body so that new treatment options for CAD 
can be developed.10  
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DISCUSSION 
 It has been shown across these studies10,13,16 that not only do endothelial 
progenitor cells have a link with endothelial dysfunction, but that levels can be used to 
predict future cardiovascular events. This measurement has now been qualified as an 
independent marker of risk. While the results of these studies do excite the topic for 
future research, the studies above were not without their own limitations. Werner et al10 
(2007) study was limited by its population size and additionally had no follow-up as a 
part of their study design. While this was not inherent to their design, this would have 
allowed for more credibility to be given to their results, as these correlations could have 
been tested over time. Due to the fact that this study started with such a small sample 
size, it is difficult to extrapolate these results confidently across the general population. 
 Schmidt-Lucke et al13 was another underpowered study with only having a 
population size of 120 total subjects with only 11 CV events. This is an unfortunate 
limitation because this study was able to demonstrate a dose-response sort of relationship 
with EPC levels and CV outcomes as well as a large treatment effect and due to its earlier 
limitation no more weight can be given this study’s drawn conclusions. One additional 
considered limitation was neglecting to mention the discussion of blinding between the 
ones manipulating the data and patients results, however, with the objectivity of the 
resultant data this was not viewed as a serious limitation. 
 One important aspect was that both Schmidt-Lucke et al13 and Werner et al16 
(2005) did have the additional element of following its subjects over time and plotting 
events on a survival curve. Werner et al16 (2005), was a well done observational trial, that 
with a large treatment effect and dose-response relationship with EPC levels was able to 
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give high quality results as this study was not limited the was the others were with small 
sample sizes. As stated above, all these studies10,13,16 were able to show the connection 
between EPCs and endothelial dysfunction, also as a prediction tool for future 
cardiovascular events. These authors recognize that in practical laboratory purposes, the 
number of cells would be much more feasible number to ascertain as opposed to CFU-EC 
numbers which can take weeks to retrieve.10 It has also been shown that age and positive 
family history of premature CAD were shown to independently predict reduced EPC 
levels showing that these risk factors have a strong influence on EPC levels.13 Other 
factors that influence individuals EPC numbers, functional ability, and response to 
endothelial injury need to be further explored.10,13,16 
It has been shown that there is a clear association between the numbers of cardiac 
risk factors an individual has and EPC senescence in healthy individuals, this indicates 
that CVD risk factors not only lead to endothelial dysfunction but also EPC 
dysfunction.14 Studies have looked at this specific issue and found that persons at risk for 
or with established CAD have a 40% reduction in EPC count, reduced migratory capacity 
of EPCs.14,18 Smoking has the strongest negative correlation to EPC number and it has 
been seen that smokers can have a two to three fold decrease in EPC count.19 Men who 
are more advanced in age (56-70 years old) showed a 70% reduction in EPC numbers and 
50% reduction in migratory capacity when compared to those in a 22-35 year old age 
group.20 It has also been established that those with either type I or II diabetes show up to 
50% decreases in EPC count along with a decrease in angiogenic capacity and vascular 
incorporation.21,22 The trend continues in persons with concomitant disease, those with 
chronic kidney disease can expect EPC numbers to be decreased as much as 75% with 
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subsequent decreases in migratory capacity and the cells ability to incorporate into 
developing vascular networks.23 However, this still does not leave us at the conclusion 
that presence will mitigate response. 
 It is perhaps equally important to distinguish if in fact a defective phenotype of 
EPC is as much to blame for increased endothelial dysfunction as the complete lack of 
cell numbers.8 In a study that aimed to evaluate if the administration of EPCs would 
improve CV outcomes in AMI patients,24,25 the TOPCARE-AMI trial gave subjects with 
MI 3-day old EPCs in the infarct related artery. It was shown that LVEF improved and 
infarct area decreased post EPC infusion when compared to control. This was shown 
without evidence of arrhythmias, inflammatory reactions, or obstruction of blood vessels. 
These results are complicated by the results of a similar study that used immature EPCs.26 
When CD133+ cells when used in a similar fashion, the result was the CD133+ 
administration was associated with enhanced current ischemia and need for repeat 
vascular intervention. 
  A similar finding was demonstrated by a group of Taiwanese researchers through 
research done in 2010 looking at EPC levels in patients undergoing PCI for acute MI.6 
They were first able to show that patients with ST-segment elevation myocardial 
infarctions (STEMI) were a more likely population to have lower number of EPCs.  Then 
they also found a high EPC count was more likely in subjects with concomitant 
congestive heart failure, lower EF, and more advanced Killip score. These patients also 
had lower levels of angiogenesis, and it was found through multivariate regression that a 
high EPC level was the most important independent marker that predicted a major 
adverse cardiovascular outcome in the next thirty days.6 There may be some question to 
 - 23 - Revised 04Mar2014 
these finding as these researchers measured CD31+ levels, a phenotype which has also 
been associated with endothelial microparticles instead of endothelial progenitor cells.5 
The existence of these specific microparticles has been associated with the presence of 
high risk cardiovascular lesions.5 This goes along with previous research that shows that 
there is a release or generation of these cells with an acute ischemic event,4,5 but also that 
the specific phenotype of cell is of significant importance when evaluating cellular 
function.8  This also lends credibility to the theory that persons with congestive heart 
failure27 or multiple risk factors for CAD have some degree of endothelial progenitor cell 
dysfunction and perhaps do not have the same degree of endothelial repair ability as 
someone without these comorbidities.14 
 This along with Werner et al16 (2005) showing that EPCs were not independent 
predictors of occurrence of acute myocardial infarction, prove that there is a relationship 
between these cells and there presence in acute events that we have yet to completely 
uncover. It can be inferred that in people with endothelial dysfunction, they will have an 
up-regulation of and higher amount of EPCs, functional or not. If this response causes an 
increase in dysfunctional EPCs to attempt to repair endothelial damage there can be no 
effect or perhaps even a process which worsens ones outcome.  People without 
endothelial dysfunction would presumably not have this need for endothelial remodeling 
and therefore would not have an increased number endothelial progenitor cells. This 
theory would say that context is paramount in measuring this value and a one-time 
measurement of a patient’s EPC level may not be the most helpful without first 
quantifying this persons own degree of endothelial damage.  
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 It can be described that endothelial damage represents a balance between the 
magnitude of injury and a capacity for repair.13 Since circulating endothelial cells are 
cells that are also found in the face of acute injury, a ratio of CEC to EPC may be a more 
helpful tool when trying to decide if there is indeed structural damage, and then assess the 
patient’s ability to repair that damage.5 Again, characteristics that influence these cells 
functional ability should be identified so that if possible this can be determined in some 
manner other than growing CFU-ECs. This may be the more important piece than just 
sole number count when determining a patient’s ability to repair endovascular damage. 
The other factor at play is the degree regulation of these cells that falls to regulatory 
cytokines, if the signaling pathway has some defect, there will be a problem in cells 
mobilizing to the area of injury.   
 While questions still exist of the precise mechanism of action and all influencing 
factors that act on these cells, researchers feel that monitoring levels of EPC as surrogate 
biological markers may be useful for identifying novel therapeutic approaches targeted to 
enhance endogenous vascular repair capacity, and may be able to modify the progression 
of cardiovascular disease.13 Due to the angiogenic and reparative capabilities attributed to 
EPCs, therapies that look to capitalize on this are being investigated in the fields of 
pulmonary hypertension, AMI, post- PCI, cerebral vascular events, and peripheral artery 
disease8. On top of using cell therapies in these areas, methods to increase cell numbers 
and mobilization are being investigated. It has been shown that certain drugs and 
behavior can increase these variables associated with EPCs. EPCs have been shown to 
mobilize into the bloodstream with exercise.28 This is thought to be in part secondary to 
the release of vascular endothelial growth factor (VGEF) and other cytokines.7,28 Drugs 
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that have been associated with a similar increase include statins, angiotensin-converting 
enzyme (ACE) inhibitors, erythropoietin, and insulin-like growth facor-1(IGF-1).29-32 
One issue that needs to be addressed in any therapy that looks to increase or supplement 
the number of EPCs in individuals for any treatment purpose would be patients risk for or 
history of cancer. EPCs have been shown to be sufficient for the development of tumor 
vasculature and risk exacerbating or furthering the growth of existing malignancies.33 
CONCLUSION 
 Endothelial progenitor cells have been proven to have a role in endothelial 
dysfunction, cardiovascular disease progression, and now risk assessment. While many 
factors play into the overall mechanism in which EPC affect cardiovascular risk and 
endothelial repair, monitoring blood levels of EPCs has become a feasible biomarker that 
can be added to further stratify a patients CV risk profile. While the overall evidence 
from this review falls in a moderate category based on GRADE results, a strong clinical 
foundation for this area of research currently exists in previous animal trials and 
blossoming studies. To better understand some of these complex relationships in humans, 
further in vivo trials need to be done. Additionally, more credibility could be lent to this 
topic with more well-designed, larger observational trials, double-blinded randomized 
control trials; and this can give providers set values that can be applied to the general 
public. However, the future in this area lies in the discovery of new therapeutic 
modalities that can modify cardiovascular disease progression. To do this, more has to be 
understood about factors that hold influence over EPC count, mobility, and colony 
forming ability, and how these functional performance issues specifically tie into disease 
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modification. Once this is better understood, this cell number can become more than just 
a count to determine risk, but a tool to help improve people’s lives. 
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Tables 
 
Table 1. Characteristics of Reviewed Studies 
 
a Study upgraded for RR of 4.6 and dose-gradient response to higher number of EPC correlating with decreased risk of CV deaths and 1st major CV event. 
b Study downgraded for lack of precision, study population only consisted of 120 subjects and only had a total of 11 adverse events throughout follow-up. Despite large 
treatment effect and dose-response correlation of results, study is unable to be upgraded. 
c The study shows limitations in lack of follow-up and therefore cannot be upgraded for any reason. Also, the study had a total population of 90 subjects recruited from one    
center. Although a correlation was shown, there is no documented treatment effect or dose response gradient to attempt upgrade. 
 
  
Quality Assessment  
Importance  Downgrade Criteria 
Quality 
Outcomes Design Limitations Indirectness Imprecision Inconsistency Publication bias likely 
Werner et al (2005): EPC and CV outcomes16   
First Major CV event Prospective 
 Observational 
 
 No serious 
limitations 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies No bias likely High
a  
Critical 
Death from CV cause Critical 
Schmidt-Lucke et al: Reduced EPC predicts future CV events13   
First major CV event Prospective  Observational 
No serious 
limitations 
No serious 
indirectness 
Serious 
imprecisionb  
No serious 
inconsistencies No bias likely 
Very 
Low  Critical 
Werner et al (2007): EPC correlate w/ endothelial function in patients w/ CAD10   
Low EPC correlate to 
severe endothelial 
dysfxn Prospective  
Observational 
Serious 
limitationsc 
No serious 
indirectness 
Serious 
imprecisionc 
No serious 
inconsistencies No bias likely 
Very 
Low 
Important 
EPC function 
correlate with 
endothelial fxn 
Important 
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Table 2. Summary of Findings 
 
 
 
 
 
Study 
Outcomes Number of Patients Results 
Werner et al(2005) 
Low EPC 
levels 
(n = 168) 
High(normal) 
EPC 
(n = 167) 
RR HR 
 
Adj. HR 
 
First major CV event (AMI, hospitalization, 
revascularization, death from CV cause)  
0.72 (0.61-0.86) 
P <0.001 
 
0.74 (0.62-0.89) 
P- 0.002 
 
Death from CV cause 14 (8.3%) 3 (1.8%) 4.63 (1.35-15.84) P < 0.0001 
0.45 (0.25-0.81) 
P - 0.007 
 
0.31 (0.16-0.63) 
P – 0.001 
 
 
Schimdt-Lucke et al Events  Non-Events Crude RR Disease activity adjusted RR 
RF and Disease 
Adjusted RR 
First major CV event  (HR for MACE with 95% CI) 11 109 6.3 (1.8-21.8) P – 0.003 
4.2 (1.1-16.0) 
P – 0.032 
 
3.9 (1.1-14.6) 
P – 0.036 
 
 
Werner et al(2007) CD34+/KDR+ CD133+   RF adjusted P-value Colony forming Fxn 
 
RF Adjusted 
Low EPC correlate to severe endothelial dysfxn 
Regression and P value 
R = 0.427 
P <0.001 
R = 0.239 
P = 0.024 
CD34+/KDR+ 
<0.001 
CD133+  = 0.017 
 
EPC function correlate with endothelial fxn 
Regression and P value  
R = 0.271 
P = 0.038 
 
R = 0.271 
P = 0.352 
 
